Business
Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update
FLORHAM PARK, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the
About this update from Cellectar Biosciences, Inc.
[{"type":"text","content":"FLORHAM PARK, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2019 and provided a corporate update.\n Fourth Quarter and Recent Corporate Highlights Announced CLR 131 achieved primary efficacy endpoints from its Phase 2 CLOVER-1 study in relapsed/refractory B-cell lymphomas and completion of the Phase 1 relapsed/refractory multiple myeloma Dose Escalation study. The data showed: ○ 42.8% overall response rate (ORR) in median 6th line treatment of multiple myeloma at the 75mCi total body dose ○ 81.8% of the multiple myeloma patients across all therapeutic doses tested experienced tumor reduction with a strong dose response ○ 100% ORR and 25% complete response (CR) seen in lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia (LPL/WM) patients ○ 42.0% ORR and 11% CR in all non-Hodgkin’s lymphoma (NHL) patients Received Orphan Drug Designation for CLR 131 in lymphoplasmacytic lymphoma (LPL) from the U.S. Food and Drug Administration Oral presentation at the American Society of Hematology (ASH) Conference entitled “Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma” Oral presentation at the European Society of Medical Oncology (ESMO) Congress entitled “Interim Evaluation of a Targeted Radiotherapeutic, CLR 131, in Relapsed/Refractory Diffuse Large B-cell Lymphoma Patients” Scientific conference poster presentations during the quarter included:○ American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium entitled “Phospholipid ether delivery vehicle shows specificity for a broad range of tumor cells and provides a novel and improved approach for targeted therapy” ○ AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference entitled “CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors”○ UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology entitled “Preclinical evaluation of a novel phospholipid drug conjugate, CLR 2000045 with a combretastatin A-4 analogue for improved breast cancer therapy” Strengthened the management team ...